Cargando…

Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma

BACKGROUND: Circulating tumour DNA (ctDNA) monitoring is a new technology that detects cancer DNA fragments in blood circulation. Regular monitoring with ctDNA has the potential to detect and treat cancer relapse earlier, but there is little evidence on patient acceptability. This study examines the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woof, Victoria G., Lee, Rebecca J., Lorigan, Paul, French, David P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927744/ https://www.ncbi.nlm.nih.gov/pubmed/35301436 http://dx.doi.org/10.1038/s41416-022-01766-x

Ejemplares similares

Circulating Tumour DNA in Melanoma—Clinic Ready?
por: Tivey, Ann, et al.
Publicado: (2022)

Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture
por: Beasley, Aaron B., et al.
Publicado: (2021)

Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series
por: Ji, Hongyan, et al.
Publicado: (2021)

Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma
por: Openshaw, Mark R., et al.
Publicado: (2020)

Psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma
por: Brown, J E, et al.
Publicado: (2000)

Circulating tumor DNA in early-stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?
por: af Hällström, Taija M, et al.
Publicado: (2015)

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma
por: Lee, R J, et al.
Publicado: (2018)

Circulating Cell-Free Tumour DNA for Early Detection of Pancreatic Cancer
por: Jaworski, Jedrzej J., et al.
Publicado: (2020)

Detection of metastases using circulating tumour DNA in uveal melanoma
por: Beasley, Aaron B., et al.
Publicado: (2023)

Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma
por: Anand, Kartik, et al.
Publicado: (2019)

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
por: McEvoy, Ashleigh C., et al.
Publicado: (2018)

Circulating Tumor DNA in the Management of Early-Stage Breast Cancer
por: Vlataki, Katerina, et al.
Publicado: (2023)

Monitoring gastric cancer progression with circulating tumour DNA
por: Hamakawa, T, et al.
Publicado: (2015)

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer
por: Jeannot, Emmanuelle, et al.
Publicado: (2021)

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
por: Chang-Hao Tsao, Simon, et al.
Publicado: (2015)

Circulating tumour cell combined with DNA methylation for early detection of hepatocellular carcinoma
por: Liang, Wenjin, et al.
Publicado: (2022)

Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
por: Hong, Xin, et al.
Publicado: (2018)

Screening for Circulating Tumour Cells Allows Early Detection of Cancer and Monitoring of Treatment Effectiveness: An Observational Study
por: Ried, Karin, et al.
Publicado: (2017)

Role of circulating tumor DNA in the management of early‐stage lung cancer
por: Zhao, Heng, et al.
Publicado: (2018)

Clinical value of early detection of circulating tumour DNA-BRAF(V600mut) in patients with metastatic melanoma treated with a BRAF inhibitor
por: Louveau, Baptiste, et al.
Publicado: (2017)

Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
por: Gale, D., et al.
Publicado: (2022)

Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma
por: Lucci, Anthony, et al.
Publicado: (2023)

High mutation burden of circulating cell‐free DNA in early‐stage breast cancer patients is associated with a poor relapse‐free survival
por: Kujala, Jouni, et al.
Publicado: (2020)

What are the views of three key stakeholder groups on extending the breast screening interval for low‐risk women? A secondary qualitative analysis
por: Taylor, Grace, et al.
Publicado: (2022)

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
por: Gremel, G., et al.
Publicado: (2016)

Disease mapping of early- and late-stage cancer to monitor inequalities in early detection: a study of cutaneous malignant melanoma
por: Strömberg, Ulf, et al.
Publicado: (2020)

Can circulating tumor DNA be used for direct and early stage cancer detection?
por: Diamandis, Eleftherios P, et al.
Publicado: (2017)

Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients
por: Yang, Ying-Chi, et al.
Publicado: (2018)

Molecular detection of persistent postoperative circulating tumour cells in stages II and III colon cancer patients via multiple blood sampling: prognostic significance of detection for early relapse
por: Lu, C-Y, et al.
Publicado: (2011)

Physical activity of early stage melanoma survivors()()
por: Robinson, J.K.
Publicado: (2018)

Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer
por: Lyskjær, Iben, et al.
Publicado: (2019)

Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer
por: Huang, Lei, et al.
Publicado: (2023)

Biomarkers in Early Diagnosis and Early Stage Lung Cancer: The Clinician’s Point of View
por: Gasparri, Roberto, et al.
Publicado: (2020)

Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2023)

Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Circulating Tumour DNA Analysis for Tumour Genome Characterisation and Monitoring Disease Burden in Extramedullary Multiple Myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2018)

Detection of clustered circulating tumour cells in early breast cancer
por: Krol, Ilona, et al.
Publicado: (2021)

Circulating tumour cells for early detection of clinically relevant cancer
por: Lawrence, Rachel, et al.
Publicado: (2023)

A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer
por: Molloy, T J, et al.
Publicado: (2011)

Early Stage Relapsing Polychondritis Diagnosed by Nasal Septum Biopsy
por: Kobayashi, Takaaki, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v43jukpshnjn44ijkco0jpjaq6